ReviewJournal of inflammation research2026
The mtDNA-cGAS-STING Axis in Acute Kidney Injury and Maladaptive Repair: Preclinical Evidence for Traditional Chinese Medicine and Natural Product-Based Interventions.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a heterogeneous syndrome characterized by substantial variation in etiology, clinical course, and recovery. Persistent tubular stress, mitochondrial dysfunction, and dysregulated inflammatory and immune responses can prolong tissue injury and lead to incomplete kidney recovery and maladaptive repair. When released into the cytosol, mitochondrial DNA (mtDNA) can activate cyclic GMP-AMP synthase (cGAS), which generates 2',3'-cGAMP and activates stimulator of interferon genes (STING). Downstream TBK1-IRF3 and NF-κB signaling programs amplify inflammation, regulated cell death, and failed repair. This structured narrative review follows the sequence of mitochondrial injury, mtDNA release, cGAS-STING activation, inflammation and regulated cell death, and maladaptive repair. We examine how these mechanisms vary across AKI etiologies, cell types, and disease stages and critically appraise preclinical evidence for traditional Chinese medicine (TCM) formulas and preparations, bioactive fractions and extracts, isolated natural products, and natural product-based delivery systems. Genetic and pharmacological studies support the involvement of this axis in selected AKI models. However, the mitochondrial origin of cGAS-sensed cytosolic DNA, the requirement for cGAS-STING signaling in observed protective effects, and the relevance of these mechanisms to human AKI remain incompletely established. Most TCM and natural product studies use cisplatin models and initiate treatment before or at the time of injury; they generally report parallel improvements in kidney injury endpoints and reductions in pathway-associated markers. Thus, selected interventions show preclinical renoprotective activity in specific models, but neither clinical efficacy nor in vivo pathway dependence has been demonstrated. Future translational studies should prioritize post-injury administration, causal pathway validation, kidney-compartment exposure, safety assessment, and functional testing in human-relevant systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.